You call that sequencing? The question isn’t one you’d expect to hear if you were sequencing DNA or RNA. But proteins? You bet. Protein sequencing poses unique challenges—too many to even mention here. Suffice it to say, protein sequencing has yet to do for proteomics what the DNA and RNA sequencing has done for genomics and transcriptomics. But that’s starting to change. Proteomics stands to benefit not only from improved mass spec technologies, but also—as discussed in GEN’s August issue—from single-molecule immobilization/sequential labeling technologies. Of course, protein sequencing isn’t the only topic where impertinence should give way to reasonable skepticism. Take artificial intelligence (AI). In GEN’s August issue, this much-hyped topic is given a sober look in two articles: one on AI-enhanced clinical trials, and one on AI-enhanced biomanufacturing. Both articles relate how limited AI can be—absent the influence of human intelligence. Other topics in the August issue include “defense in depth” strategies against emergent infectious diseases, and opportunities for more telling (and more sparing) use of animal models.